THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER

Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist. The method includes, consisting of, and/orconsisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I), wherein R1, G, R10, and R11 are defined herein. 本发明公开了用于治疗和/或改善有需要的受试者包括哺乳动物和/或人中与去势抵抗性前列腺癌相关的AR突变体受体相关联的疾病、综合征、障碍或病症的化合物、组合物和方法，所述受试者已证明对第代或第二代AR拮抗剂具有抗性，所述方法包括向对其有需要的受试者施用治疗有效量的式(I)化合物，由上述组成和/或基本上由上述组成，其中R、G、R和R如本文定义。